Physician profile
Anna Malgorzata Lang
NPI 1235556432
$4,257.11
in general payments reported to CMS, 2019-2025
11 companies · $31.38 in 2025
The $31.38 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.65 · 2021: $122 · 2022: $23.22 · 2023: $613 · 2024: $3,453 · 2025: $31.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,547 · Food and Beverage: $1,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,546.89 |
| Food and Beverage | $1,550.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $2,825.37 | 2023-2024 | Joenja |
| Genzyme Corporation | $373.26 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $326.62 | 2021-2024 | Fasenra, Airsupra |
| Biocryst US Sales Co., LLC | $314.12 | 2022-2024 | Orladeyo |
| Blueprint Medicines Corporation | $143.57 | 2024-2025 | Ayvakit |
| Csl Behring | $107.83 | 2023-2024 | Hizentra |
| Amgen INC. | $54.87 | 2024 | Actimmune |
| Adma Biomanufacturing LLC | $46.89 | 2024 | |
| Genentech, INC. | $25.72 | 2023 | Xolair |
| Alk-Abello, INC | $24.21 | 2023 | Odactra, Ragwitek, Grastek |
| Takeda Pharmaceuticals U.S.A., INC. | $14.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.